|
|
| Product Name: | OM99-2 | | Synonyms: | OM99-2;H-GLU-VAL-ASN-[(2R,4S,5S)-5-AMINO-4-HYDROXY-2,7-DIMETHYL-OCTANOYL]-ALA-GLU-PHE-OH;EVNL-PSI-AAEF;GLU-VAL-ASN-(2R,4S,5S)-5-AMINO-*4-HYDROXY-2,7-DIMET;[2-AMINOBENZOYL-GLY1]-GALANIN FRAGMENT (1-10)-LYS(RETRO-M-NITRO-TYR) AMIDE HUMAN;[2-aminobenzoyl-gly1]-galanin fragment (1-10)-lys(retro-m-nitro-tyr) amide, human trifluoroacetate salt;glu-val-asn-[(2r,4s,5s)-5-amino-4-hydroxy-2,7-dimethyloctanoyl]-ala-glu-phe;OM99-2;[2-AMINOBENZOYL-GLY1]-GALANIN FRAGMENT (1-10)-LYS(RETRO-M-NITRO-TYR) AMIDE, HUMAN TRIFLUOROACETATE SALT | | CAS: | 314266-76-7 | | MF: | C41H64N8O14 | | MW: | 892.99 | | EINECS: | | | Product Categories: | Galanin Degrading Zinc-MetallopeptidaseEnzyme Substrates;Galanin degrading zinc-metallopeptidasePeptides for Cell Biology;Enzyme Substrates;Galanins;Neuropeptides;Protease Substrates;Substrates by Enzyme | | Mol File: | 314266-76-7.mol |  |
| | OM99-2 Chemical Properties |
| Boiling point | 1346.5±65.0 °C(Predicted) | | density | 1.289±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | form | solid | | pka | 3.48±0.10(Predicted) | | InChIKey | JCNFYXCBSRPSLY-QYTLZHMISA-N |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | Storage Class | 10 - Combustible liquids |
| | OM99-2 Usage And Synthesis |
| Uses | OM99-2, an eight residue peptidomimetic, tight-binding inhibitor of human brain memapsin 2 with a Ki value of 9.58 nM[1]. OM99-2 is significantly advanced the development of BACE1 inhibitor[2]. OM99-2 has the potential for the research of the Alzheimer's disease[3]. | | Biological Activity | Cell permeable: no', 'Primary Target
human brain memapsin 2', 'Product does not compete with ATP.', 'Reversible: no', 'Target Ki: 1.6 nM against recombinant memapsin 2; 9.58 nM against recombinant pro-memapsin 2; 48 nM against cathepsin D | | IC 50 | BACE1 | | References | [1] Ghosh AK, et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase). J Am Chem Soc. 2000;122(14):3522-3523. DOI:10.1021/ja000300g
[2] Zhao J, et al. Targeting Amyloidogenic Processing of APP in Alzheimer's Disease. Front Mol Neurosci. 2020;13:137. Published 2020 Aug 4. DOI:10.3389/fnmol.2020.00137
[3] Dash C, et al. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol. 2003;38(2):89-119. DOI:10.1080/713609213
[4] Park H, et al. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc. 2003;125(52):16416-16422. DOI:10.1021/ja0304493 |
| | OM99-2 Preparation Products And Raw materials |
|